The gut microbiome and irritable bowel syndrome.

F1000Research

Volumn 7, Issue , 2018, Pages

  Chey, William ^a   Menees, Stacy ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

Abdominal pain; Bloating; Diarrhea; Metabolome; Microbiome

Indexed keywords

ANTIBIOTIC AGENT; MACROLIDE; PREBIOTIC AGENT; PROBIOTIC AGENT; RIFAXIMIN; TETRACYCLINE;

ABDOMINAL PAIN; ANTIBIOTIC THERAPY; BACTERIAL OVERGROWTH; BLOATING; DIARRHEA; DIET THERAPY; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; INTESTINE FLORA; IRRITABLE COLON; METABOLOME; MICROBIAL COMMUNITY; NONHUMAN; PATHOGENESIS; REVIEW;

EID: 85050019812     PISSN: None     EISSN: 20461402     Source Type: Journal    
DOI: 10.12688/f1000research.14592.1     Document Type: Review

References (72)

1. Mearin F Lacy BE Chang L : Bowel Disorders. Gastroenterology. 2016;150(6):1393-1407.e5, pii: S0016-5085(16)00222-5. 27144627 10.1053/j.gastro.2016.02.031
2. Lovell RM Ford AC : Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712-721.e4. 22426087 10.1016/j.cgh.2012.02.029
3. Gralnek IM Hays RD Kilbourne A : The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;119(3):654-60. 10982758 10.1053/gast.2000.16484
4. Lembo AJ : The Clinical and Economic Burden of Irritable Bowel Syndrome. Pract Gastroenterol. 2007;31:3-9.
5. Turnbaugh PJ Ley RE Hamady M : The human microbiome project. Nature. 2007;449(7164):804-10. 17943116 10.1038/nature06244 3709439
6. Marchesi JR : Prokaryotic and eukaryotic diversity of the human gut. Adv Appl Microbiol. 2010;72:43-62. 20602987 10.1016/S0065-2164(10)72002-5
7. Breitbart M Haynes M Kelley S : Viral diversity and dynamics in an infant gut. Res Microbiol. 2008;159(5):367-73. 18541415 10.1016/j.resmic.2008.04.006
8. Hugon P Dufour JC Colson P : A comprehensive repertoire of prokaryotic species identified in human beings. Lancet Infect Dis. 2015;15(10):1211-9. 26311042 10.1016/S1473-3099(15)00293-5
9. Li J Jia H Cai X : An integrated catalog of reference genes in the human gut microbiome. Nat Biotechnol. 2014;32(8):834-41. 24997786 10.1038/nbt.2942
10. Rothschild D Weissbrod O Barkan E : Environment dominates over host genetics in shaping human gut microbiota. Nature. 2018;555(7695):210-5. 29489753 10.1038/nature25973 F1000 Recommendation
11. Barbara G Feinle-Bisset C Ghoshal UC : The Intestinal Microenvironment and Functional Gastrointestinal Disorders. Gastroenterology. 2016;150(6):1305-1318.e8, pii: S0016-5085(16)00219-5. 27144620 10.1053/j.gastro.2016.02.028 F1000 Recommendation
12. Ohman L Simrén M : Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010;7(3):163-73. 20101257 10.1038/nrgastro.2010.4
13. Halvorson HA Schlett CD Riddle MS : Postinfectious irritable bowel syndrome--a meta-analysis. Am J Gastroenterol. 2006;101(8):1894-9; quiz 1942. 16928253 10.1111/j.1572-0241.2006.00654.x
14. Klem F Wadhwa A Prokop LJ : Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis. Gastroenterology. 2017;152(5):1042-1054.e1. 28069350 10.1053/j.gastro.2016.12.039 5367939 F1000 Recommendation
15. Labus JS Hollister EB Jacobs J : Differences in gut microbial composition correlate with regional brain volumes in irritable bowel syndrome. Microbiome. 2017;5(1):49. 28457228 10.1186/s40168-017-0260-z 5410709 F1000 Recommendation
16. Jeffery IB O'Toole PW Öhman L : An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2012;61(7):997-1006. 22180058 10.1136/gutjnl-2011-301501 F1000 Recommendation
17. Tap J Derrien M Törnblom H : Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome. Gastroenterology. 2017;152(1):111-123.e8. 27725146 10.1053/j.gastro.2016.09.049 F1000 Recommendation
18. Carroll IM Ringel-Kulka T Keku TO : Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2011;301(5):G799-807. 21737778 10.1152/ajpgi.00154.2011 3220325
19. Carroll IM Ringel-Kulka T Siddle JP : Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 2012;24(6):521-30, e248. 22339879 10.1111/j.1365-2982.2012.01891.x 3975596
20. Botschuijver S Roeselers G Levin E : Intestinal Fungal Dysbiosis Is Associated With Visceral Hypersensitivity in Patients With Irritable Bowel Syndrome and Rats. Gastroenterology. 2017;153(4):1026-39. 28624575 10.1053/j.gastro.2017.06.004 F1000 Recommendation
21. Justus PG Fernandez A Martin JL : Altered myoelectric activity in the experimental blind loop syndrome. J Clin Invest. 1983;72(3):1064-71. 6350361 10.1172/JCI111031 1129274
22. Vantrappen G Janssens J Hellemans J : The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. J Clin Invest. 1977;59(6):1158-66. 864008 10.1172/JCI108740 372329
23. Coelho AM Fioramonti J Buéno L : Systemic lipopolysaccharide influences rectal sensitivity in rats: role of mast cells, cytokines, and vagus nerve. Am J Physiol Gastrointest Liver Physiol. 2000;279(4):G781-90. 11005766 10.1152/ajpgi.2000.279.4.G781
24. Giannella RA Rout WR Toskes PP : Jejunal brush border injury and impaired sugar and amino acid uptake in the blind loop syndrome. Gastroenterology. 1974;67(5):965-74. 4426497
25. Hofmann AF Poley JR : Role of bile acid malabsorption in pathogenesis of diarrhea and steatorrhea in patients with ileal resection. I. Response to cholestyramine or replacement of dietary long chain triglyceride by medium chain triglyceride. Gastroenterology. 1972;62(5):918-34. 5029077
26. Hajjar JJ Khuri RN Bikhazi AB : Effect of bile salts on amino acid transport by rabbit intestine. Am J Physiol. 1975;229(2):518-23. 1163679 10.1152/ajplegacy.1975.229.2.518
27. Deitch EA Specian RD Berg RD : Endotoxin-induced bacterial translocation and mucosal permeability: role of xanthine oxidase, complement activation, and macrophage products. Crit Care Med. 1991;19(6):785-91. 2055056
28. Riordan SM McIver CJ Thomas DH : Luminal bacteria and small-intestinal permeability. Scand J Gastroenterol. 1997;32(6):556-63. 9200287 10.3109/00365529709025099
29. Ghoshal UC Shukla R Ghoshal U : Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy. Gut Liver. 2017;11(2):196-208. 28274108 10.5009/gnl16126 5347643 F1000 Recommendation
30. Wang X Gibson GR : Effects of the in vitro fermentation of oligofructose and inulin by bacteria growing in the human large intestine. J Appl Bacteriol. 1993;75(4):373-80. 8226394 10.1111/j.1365-2672.1993.tb02790.x
31. Olesen M Gudmand-Hoyer E : Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome. Am J Clin Nutr. 2000;72(6):1570-5. 11101487 10.1093/ajcn/72.6.1570
32. Paineau D Payen F Panserieu S : The effects of regular consumption of short-chain fructo-oligosaccharides on digestive comfort of subjects with minor functional bowel disorders. Br J Nutr. 2008;99(2):311-8. 17697398 10.1017/S000711450779894X
33. Silk DB Davis A Vulevic J : Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 2009;29(5):508-18. 19053980 10.1111/j.1365-2036.2008.03911.x F1000 Recommendation
34. Alexea O Bacarea V Piqué N : The combination of oligo- and polysaccharides and reticulated protein for the control of symptoms in patients with irritable bowel syndrome: Results of a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial. United European Gastroenterol J. 2016;4(3):455-65. 27403313 10.1177/2050640615615050 4924437 F1000 Recommendation
35. O'Mahony L McCarthy J Kelly P : Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128(3):541-51. 15765388 10.1053/j.gastro.2004.11.050 F1000 Recommendation
36. Verdú EF Bercik P Verma-Gandhu M : Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut. 2006;55(2):182-90. 16105890 10.1136/gut.2005.066100 1856497
37. Kamiya T Wang L Forsythe P : Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats. Gut. 2006;55(2):191-6. 16361309 10.1136/gut.2005.070987 1856513
38. Ford AC Quigley EM Lacy BE : Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109(10):1547-61; quiz 1546, 1562. 25070051 10.1038/ajg.2014.202
39. Dinan TG Cryan JF : The Microbiome-Gut-Brain Axis in Health and Disease. Gastroenterol Clin North Am. 2017;46(1):77-89. 28164854 10.1016/j.gtc.2016.09.007 F1000 Recommendation
40. McKean J Naug H Nikbakht E : Probiotics and Subclinical Psychological Symptoms in Healthy Participants: A Systematic Review and Meta-Analysis. J Altern Complement Med. 2017;23(4):249-58. 27841940 10.1089/acm.2016.0023 F1000 Recommendation
41. Pinto-Sanchez MI Hall GB Ghajar K : Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. Gastroenterology. 2017;153(2):448-459.e8. 28483500 10.1053/j.gastro.2017.05.003 F1000 Recommendation
42. Dethlefsen L Huse S Sogin ML : The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 2008;6(11):e280. 19018661 10.1371/journal.pbio.0060280 2586385 F1000 Recommendation
43. Dethlefsen L Relman DA : Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A. 2011;108 Suppl 1:4554-61. 20847294 10.1073/pnas.1000087107 3063582
44. Villarreal AA Aberger FJ Benrud R : Use of broad-spectrum antibiotics and the development of irritable bowel syndrome. WMJ. 2012;111(1):17-20. 22533211
45. Menees SB Maneerattannaporn M Kim HM : The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012;107(1):28-35; quiz 36. 22045120 10.1038/ajg.2011.355
46. Lembo A Pimentel M Rao SS : Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. Gastroenterology. 2016;151(6):1113-21. 27528177 10.1053/j.gastro.2016.08.003
47. Schoenfeld P Pimentel M Chang L : Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2014;39(10):1161-8. 24697851 10.1111/apt.12735 4112801
48. Fodor AA Pimentel M Chey WD : Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome. Gut Microbes. 2018;1-28. 29708822 10.1080/19490976.2018.1460013
49. Gupta A Chey WD : Breath Testing for Small Intestinal Bacterial Overgrowth: A Means to Enrich Rifaximin Responders in IBS Patients? Am J Gastroenterol. 2016;111(3):305-6. 26925880 10.1038/ajg.2016.32
50. Ghoshal UC Srivastava D Misra A : A proof-of-concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small-intestinal bacterial overgrowth: a randomized, double-blind, placebo-controlled trial. Eur J Gastroenterol Hepatol. 2016;28(3):281-9. 26731696 10.1097/MEG.0000000000000557 F1000 Recommendation
51. Rezaie A : Lactulose Breath Testing Predicts the Response to Rifaximin. Am J Gastroenterol. 2017;112(S1):S227.
52. David LA Maurice CF Carmody RN : Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559-63. 24336217 10.1038/nature12820 3957428 F1000 Recommendation
53. Muegge BD Kuczynski J Knights D : Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans. Science. 2011;332(6032):970-4. 21596990 10.1126/science.1198719 3303602 F1000 Recommendation
54. Singh RK Chang HW Yan D : Influence of diet on the gut microbiome and implications for human health. J Transl Med. 2017;15(1):73. 28388917 10.1186/s12967-017-1175-y 5385025 F1000 Recommendation
55. Austin GL Dalton CB Hu Y : A very low-carbohydrate diet improves symptoms and quality of life in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol. 2009;7(6):706-708.e1. 19281859 10.1016/j.cgh.2009.02.023 2693479 F1000 Recommendation
56. Shepherd SJ Parker FC Muir JG : Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol. 2008;6(7):765-71. 18456565 10.1016/j.cgh.2008.02.058
57. Shepherd SJ Gibson PR : Fructose malabsorption and symptoms of irritable bowel syndrome: guidelines for effective dietary management. J Am Diet Assoc. 2006;106(10):1631-9. 17000196 10.1016/j.jada.2006.07.010
58. Staudacher HM Whelan K Irving PM : Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J Hum Nutr Diet. 2011;24(5):487-95. 21615553 10.1111/j.1365-277X.2011.01162.x
59. Staudacher HM Whelan K : The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS. Gut. 2017;66(8):1517-27. 28592442 10.1136/gutjnl-2017-313750 F1000 Recommendation
60. Zhou S Eswaran SL Wu X : Low FODMAP diet modulates visceral nociception by changing gut microbiota and intestinal permeability in IBS. Gastroenterology. 2016;150(4):S63-S64. 10.1016/S0016-5085(16)30335-3
61. Halmos EP Christophersen CT Bird AR : Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut. 2015;64(1):93-100. 25016597 10.1136/gutjnl-2014-307264 F1000 Recommendation
62. Tuck CJ Taylor KM Gibson PR : Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by α-Galactosidase Treatment. Am J Gastroenterol. 2018;113(1):124-34. 28809383 10.1038/ajg.2017.245 F1000 Recommendation
63. Pinn DM Aroniadis OC Brandt LJ : Is fecal microbiota transplantation the answer for irritable bowel syndrome? A single-center experience. Am J Gastroenterol. 2014;109(11):1831-2. 25373585 10.1038/ajg.2014.295
64. Holvoet T Joossens M Wang J : Assessment of faecal microbial transfer in irritable bowel syndrome with severe bloating. Gut. 2017;66(5):980-2. 27511198 10.1136/gutjnl-2016-312513 5531219 F1000 Recommendation
65. Mizuno S Masaoka T Naganuma M : Bifidobacterium-Rich Fecal Donor May Be a Positive Predictor for Successful Fecal Microbiota Transplantation in Patients with Irritable Bowel Syndrome. Digestion. 2017;96(1):29-38. 28628918 10.1159/000471919 5637308 F1000 Recommendation
66. Johnsen PH Hilpüsch F Cavanagh JP : Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol. 2018;3(1):17-24. 29100842 10.1016/S2468-1253(17)30338-2 F1000 Recommendation
67. Holvoet T Joossens M Boelens J : 617 - Fecal Microbiota Transplantation in Irritable Bowel Syndrome with Predominant Abdominal Bloating: Results from a Double Blind, Placebo-Controlled Clinical Trial. Gastroenterology. 2018;154(6 Supplement 1):S-130. 10.1016/S0016-5085(18)30860-6
68. Aroniadis OC Brandt LJ Oneto C : 742 - A Double-Blind, Randomized, Placebo-Controlled Trial of Fecal Microbiota Transplantation Capsules (FMTC) for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D). Gastroenterology. 2018;154(6 Supplement 1):S-154-S-155. 10.1016/S0016-5085(18)30932-6
69. Halkjaer S Christiensen A Lo B : 914 - Fecal Microbiota Transplantation Alters Gut Microbiota in Patients with Irritable Bowel Syndrome: Results from a Randomized, Double-Blind Placebo Controlled Study. Gastroenterology. 2018;154(6 Supplement 1):S-181. 10.1016/S0016-5085(18)31016-3
70. Chumpitazi BP Cope JL Hollister EB : Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Aliment Pharmacol Ther. 2015;42(4):418-27. 26104013 10.1111/apt.13286 4514898 F1000 Recommendation
71. McIntosh K Reed DE Schneider T : FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut. 2017;66(7):1241-51. 26976734 10.1136/gutjnl-2015-311339 F1000 Recommendation
72. Rossi M Aggio R Staudacher HM : Volatile Organic Compounds in Feces Associate With Response to Dietary Intervention in Patients With Irritable Bowel Syndrome. Clin Gastroenterol Hepatol. 2018;16(3):385-391.e1. 28993261 10.1016/j.cgh.2017.09.055 F1000 Recommendation